Month: March 2023

NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) — Silver Spike Investment Corp. (“Silver Spike” or the “Company”), a specialty finance company that was formed to invest across the cannabis ecosystem through investments primarily in the form of direct loans to privately held cannabis companies, today announced its financial results for the fiscal year ended December 31, 2022. Quarter Ended 12/31/22 HighlightsTotal investment income of $2.0 million Net investment income of $1.4 million, or $0.23 per share Investment portfolio of $50.3 million at fair value Net asset value (“NAV”) per share increased to $13.91 on December 31, 2022 from $13.73 on September 30, 2022Scott Gordon, Chairman and Chief Executive Officer of Silver Spike, commented, “We continue to build a robust portfolio of loans to the cannabis industry’s top operators,...

~ Q4 Revenue Increased 579% to $20.0 Million Compared to Q4 2021; Full Year 2022 Revenue Increased 316% ~ ~ Achieved Q4 2022 Company Record Key Performance Indicators ~ ~ Average Global Monthly Active Users Increased to 80 Million, Up 142% Compared to Q4 2021 ~ ~ Completed Significant Milestone with Beta Launch of Pre-Roll Video Ads on Advertising Center ~ LONGBOAT KEY, Fla., March 30, 2023 (GLOBE NEWSWIRE) — Rumble Inc. (“Rumble”) (NASDAQ: RUM), the popular video-sharing platform, announced today financial results for the fiscal quarter and full year ended December 31, 2022. Q4 and Full Year 2022 Key HighlightsAverage global Monthly Active Users (“MAUs”) increased 142% to 80 million, a company record, compared to 33 million in the fourth quarter of 2021. Of the 80 million, 65 million were based in the U.S. and Canada, compared...

Conference Call on Thursday, March 30, 2023, at 9 p.m. ET with Accompanying Investor Presentation BEIJING, March 30, 2023 (GLOBE NEWSWIRE) — ATA Creativity Global (“ACG” or the “Company”, Nasdaq: AACG), an international educational services company focused on providing quality learning experiences that cultivate and enhance students’ creativity, today announced preliminary unaudited financial results for the quarter and year ended December 31, 2022 (“Fourth Quarter 2022” and “Fiscal Year 2022”, respectively). Fourth Quarter 2022 and Fiscal Year 2022 HighlightsFourth Quarter 2022 net revenues increased 8.2% to RMB78.5 million (US$11.4 million), from RMB72.6 million in the prior-year period. Fourth Quarter 2022 net income attributable to ACG was RMB2.0 million (US$0.3 million), compared to net loss of RMB2.5 million in the prior-year...

Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia and received feedback from the FDA outlining a clear path forward for the program Entered into co-development agreement with Formosa Pharmaceuticals Company to host conference call and webcast today, March 30th, at 4:30 pm ET NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced its financial and operating results for the fourth...

Reports Continued Growth of RELI Exchange Platform Company to Host Conference Call Today at 4:30 PM Eastern Time LAKEWOOD, N.J., March 30, 2023 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: RELI; RELIW) (“Reliance”, “we” or the “Company”), today provided a business update and reported financial results for the year-ended December 31, 2022. Ezra Beyman, CEO of Reliance, commented, “We are extremely pleased to report a 73% increase in revenue in 2022 as compared to 2021. This achievement was due to the growth and overall solid performance from our ten operating subsidiaries. We are also very proud of our most recent business formation, RELI Exchange, built on the foundations of Barra & Associates, an agency we acquired in April 2022. RELI Exchange is a business-to-business (B2B) InsurTech platform and agency partner...

Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., March 30, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three and twelve months ended December 31, 2022. “Last year (2022) was a year of major transformation, excitement and renewed energy for Lisata, allowing us to enter 2023 with growing momentum as we continue to build an enduring pharmaceutical company,” stated David J. Mazzo, Ph.D., Chief Executive Officer of Lisata. “We believe in the potential of our new development pipeline and take pride in the advancement of our clinical studies in oncology...

Secured meetings with U.S. and European regulatory agencies Advancing partnership activities in both the U.S. and Europe Ended 2022 fiscal year with cash and cash equivalents of $4.0 million CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2022 fiscal year ended December 31, 2022. Cary Claiborne, President and Chief Executive Officer of Adial, stated, “We made significant advancements throughout 2022. Specifically, we announced topline data from our pivotal ONWARD™ phase 3 clinical trial evaluating the efficacy, safety,...

Advanced platform achieving multiple industry breakthroughs including creation and validation of de novo antibodies using zero-shot generative AI 10 new Active Programs in 2022, exceeding full-year guidance VANCOUVER, Wash. and NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), the generative AI drug creation company, today reported financial and operating results for the fourth quarter and year ended December 31, 2022. “2022 was a transformational year for Absci that saw research collaborations with Merck and NVIDIA, and included continued strengthening of our platform, talent, and infrastructure, paving the way for an already-monumental 2023,” said Sean McClain, Founder and CEO. “What the world has been seeing over the last few months with the power of generative AI has been central...

Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line data expected in 1H 2024 Exclusive license agreement with GSK for tebipenem HBr provided Spero with $66 million upfront, a $9 million direct equity investment, and eligibility for future milestone payments and tiered royalties Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided a business...